Headquartered within steps of the USPTO with an affiliate office in Tokyo, Oblon is one of the largest law firms in the United States focused exclusively on intellectual property law.
1968
Norman Oblon with Stanley Fisher and Marvin Spivak launched what was to become Oblon, McClelland, Maier & Neustadt, LLP, one of the nation's leading full-service intellectual property law firms.
Outside the US, we service companies based in Japan, France, Germany, Italy, Saudi Arabia, and farther corners of the world. Our culturally aware attorneys speak many languages, including Japanese, French, German, Mandarin, Korean, Russian, Arabic, Farsi, Chinese.
Oblon's professionals provide industry-leading IP legal services to many of the world's most admired innovators and brands.
From the minute you walk through our doors, you'll become a valuable part of a team that fosters a culture of innovation, client service and collegiality.
The United States Patent and Trademark Office (USPTO) issued final rules implementing the inventor's oath or declaration provisions of the America Invents Act (AIA) on August 14, 2012.
November 16, 2023 - In-Person in Munich
October 27, 2023
October 3 and 5, 2023
On December 6 the U.S. Trade Representative announced its support for a delay on the vote to expand to Covid-19 waiver of the WTO Agreement on Trade-Related Aspects of Intellectual Property Rights, or TRIPS. The current waiver applies to vaccines only while the proposed expansion includes diagnostics and therapeutics. The Trade Representative wants the U.S. International Trade commission to commence a probe relating to the diagnostics and therapeutics. The current waiver covering vaccine patents under the TRIPS agreement for five years, allowing member countries to access COVID-19 patents for vaccine production and making it so the U.S. cannot enforce certain IP rights on behalf of American companies. The U.S. Chamber of Commerce opposes the expanded waiver noting that intellectual property has played a critical role in the development of vaccines, diagnostics and therapeutics and empowered companies to voluntarily license the innovative treatments worldwide.